Protara Therapeutics (TARA) Projected to Post Earnings on Tuesday

Key Points

• Protara Therapeutics (NASDAQ:TARA) is set to release its Q2 2025 earnings on August 5th, with analysts expecting a loss of ($0.43) per share.
• In its previous earnings report on May 8th, Protara beat estimates by reporting ($0.29) EPS, and it was projected to have an EPS of ($3) for both the current and next fiscal years.
• Protara Therapeutics currently has a consensus "Buy" rating from six analysts, with an average target price of $20.50, following recent upgrades by HC Wainwright and Jones Trading.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect Protara Therapeutics to post earnings of ($0.43) per share for the quarter.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.18. On average, analysts expect Protara Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Protara Therapeutics Price Performance

Shares of TARA traded down $0.04 during mid-day trading on Friday, reaching $3.06. The company's stock had a trading volume of 301,824 shares, compared to its average volume of 343,064. Protara Therapeutics has a 12-month low of $1.60 and a 12-month high of $10.48. The stock has a market cap of $118.06 million, a PE ratio of -1.78 and a beta of 1.35. The company's 50 day moving average is $3.13 and its 200 day moving average is $3.72.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Scotiabank assumed coverage on Protara Therapeutics in a report on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Monday, April 28th. Finally, Jones Trading raised Protara Therapeutics to a "strong-buy" rating and set a $21.00 price target on the stock in a research report on Thursday, May 22nd. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $20.50.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.